| 1.55 0.01 (0.65%) | 10-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.86 | 1-year : | 2.18 |
| Resists | First : | 1.6 | Second : | 1.86 |
| Pivot price | 1.5  |
|||
| Supports | First : | 1.43 | Second : | 1.34 |
| MAs | MA(5) : | 1.55 | MA(20) : | 1.47 |
| MA(100) : | 1.36 |
MA(250) : | 1.47 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 80.8 |
D(3) : | 84.5 |
| RSI | RSI(14): 61.4 |
|||
| 52-week | High : | 2.03 | Low : | 1.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OPK ] has closed below upper band by 26.8%. Bollinger Bands are 31.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.57 - 1.58 | 1.58 - 1.59 |
| Low: | 1.51 - 1.52 | 1.52 - 1.53 |
| Close: | 1.54 - 1.55 | 1.55 - 1.56 |
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Sun, 05 Oct 2025
OPKO Health (OPK): Valuation Insights as Clinical Pipeline Progress and Asset Sales Draw Investor Focus - simplywall.st
Sun, 05 Oct 2025
OPKO Health (OPK): Valuation Insights as Clinical Pipeline Progress and Asset Sales Draw Investor Focus - Sahm
Sat, 04 Oct 2025
Washington Growth Strategies LLC Has $1.79 Million Position in OPKO Health, Inc. $OPK - MarketBeat
Fri, 03 Oct 2025
OPKO Health (OPK) Is Up 7.7% After Advancing Immuno-Oncology Pipeline and CEO Boosts Stake Has the Bull Case Changed? - simplywall.st
Fri, 03 Oct 2025
Why OPKO Health (OPK) Is Up 7.7% After Advancing Immuno-Oncology Pipeline and Notable Insider Buying - Sahm
Fri, 03 Oct 2025
Opko Health (OPK) Reports Fiscal Q2 2025 Results - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 794 (M) |
| Shares Float | 377 (M) |
| Held by Insiders | 46.8 (%) |
| Held by Institutions | 26.3 (%) |
| Shares Short | 32,890 (K) |
| Shares Short P.Month | 33,040 (K) |
| EPS | -0.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.65 |
| Profit Margin | -26.7 % |
| Operating Margin | -38.3 % |
| Return on Assets (ttm) | -8.5 % |
| Return on Equity (ttm) | -13.2 % |
| Qtrly Rev. Growth | -13.9 % |
| Gross Profit (p.s.) | 0.12 |
| Sales Per Share | 0.83 |
| EBITDA (p.s.) | -0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -239 (M) |
| Levered Free Cash Flow | -186 (M) |
| PE Ratio | -5.97 |
| PEG Ratio | 0 |
| Price to Book value | 0.93 |
| Price to Sales | 1.85 |
| Price to Cash Flow | -5.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|